KEGG DRUG: Cladribine

DRUG: Cladribine

Entry

D01370                      Drug

Name

Cladribine (JAN/USP/INN);
Leustatin (TN);
Mavenclad (TN)

Product

MAVENCLAD (EMD Serono)

Generic

CLADRIBINE (Fresenius Kabi USA), CLADRIBINE (Hikma Pharmaceuticals USA), CLADRIBINE (Hisun Pharmaceuticals USA), CLADRIBINE (Hisun Pharmaceuticals USA)

Formula

C10H12ClN5O3

Exact mass

285.0629

Mol weight

285.69

Structure

Simcomp

Class

Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic

Remark

Therapeutic category:

4291

ATC code:

L01BB04 L04AA40

Product:

D01370<JP/US>

Efficacy

Antineoplastic, Antimetabolite

Disease

Hairy-cell leukemia [DS:H00006]
Multiple sclerosis [DS:H01490]

Target

RRM1 [HSA:6240] [KO:K10807]
DNA polymerase

Pathway

hsa00230

Purine metabolism

hsa00240

Pyrimidine metabolism

Interaction

Structure map

map07041

Antineoplastics - antimetabolic agents

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01B ANTIMETABOLITES
    L01BB Purine analogues
     L01BB04 Cladribine
      D01370  Cladribine (JAN/USP/INN) <JP/US>
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA40 Cladribine
      D01370  Cladribine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Antimetabolites
   Cladribine
    D01370  Cladribine (JAN/USP/INN)
Central Nervous System Agents
  Multiple Sclerosis Agents
   Cladribine
    D01370  Cladribine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D01370  Cladribine (JAN/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
  DG02018  Antimetabolite
   DG01958  Nucleic acid derivative, antineoplastic
    D01370  Cladribine
Drug classes [BR:br08332]
Antineoplastic
  DG02018  Antimetabolite
   D01370  Cladribine
Target-based classification of drugs [BR:br08310]
Enzymes
  Oxidoreductases (EC1)
   Ribonucleoside-diphosphate reductase
    RRM1
     D01370  Cladribine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D01370
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D01370

Other DBs

CAS:

4291-63-8

PubChem:

7848433

ChEBI:

567361

PDB-CCD:

CL9[PDBj]

LigandBox:

D01370

NIKKAJI:

J446.344G

LinkDB

KCF data

ATOM        19
            1   C1y C    13.2977  -19.5392
            2   C1x C    14.6838  -19.5392
            3   C1y C    15.1121  -18.2209
            4   O2x O    13.9907  -17.4062
            5   C1y C    12.8694  -18.2209
            6   N5x N    17.5130  -19.6070
            7   C8y C    17.5130  -18.2209
            8   N4y N    16.3126  -17.5278
            9   C1b C    11.6689  -17.5278
            10  O1a O    10.4685  -18.2209
            11  O1a O    12.4829  -20.6606
            12  C8y C    18.7133  -20.3000
            13  N5x N    19.9138  -19.6070
            14  C8y C    19.9138  -18.2209
            15  C8y C    18.7133  -17.5278
            16  C8x C    16.7284  -16.1436
            17  N5x N    18.2975  -16.1432
            18  X   Cl   18.7133  -21.6877
            19  N1a N    21.1159  -17.5266
BOND        21
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     1   5 1
            6     6   7 1
            7     7   8 1
            8     3   8 1 #Up
            9     5   9 1 #Up
            10    9  10 1
            11    1  11 1 #Down
            12    6  12 2
            13   12  13 1
            14   13  14 2
            15   14  15 1
            16    7  15 2
            17    8  16 1
            18   15  17 1
            19   16  17 2
            20   12  18 1
            21   14  19 1

» Japanese version » Back

DBGET integrated database retrieval system

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.